Enter your terms above and click the 'Search' button.

Showing articles 0 to 11 of 11 Filter Applied: immune checkpoint inhibitors (Click to remove) Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer Neurol 91:e985-e994, Touat, M.,et al, 2018 Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016 Pembrolizumab-Induced Migrating Cortico-Subcortical Brain Lesions Ann Neurol 89:1255-1256, Lambert, N.,et al, 2021 Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors Neurol 97:e191-e202, Nersesjan, V.,et al, 2021 Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021 Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016 JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020 Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies Neurol 92:663-674, Johansen, A.,et al, 2019 Pembrolizumab-Induced Myasthenia Gravis Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018 Neurological Immune-Related Adverse Events of Ipilimumab Pract Neurol 13:278-280, Bot, I.,et al, 2013 Showing articles 0 to 11 of 11